Base44 said its new AI model aims to be faster, burn through fewer credits, and produce better designs than frontier models.

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...